How to beat your competition
With new trial data being presented at the annual meeting of the American Society of Clinical Oncology (ASCO) today, a provocative question on the minds of many interested in hematologic malignancies is…
Do we really need yet another tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML)? Is it time to go in a new direction?
Instead I’m going to turn it around and suggest we consider the issue in an entirely different way:
What’s the best thing to do for people living with CML?
The solution lies not in the usual chestnut about having more choice or available options, but rather in how can they be helped more by having access to a different therapy? What do they gain or lose from it?
When we look at the situation in this fashion then the answer quietly speaks for itself…
To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
